BJA+Editorial+2018+(ketamine-depression)final2'.pdf (704.31 kB)
Download file

Ketamine and depression

Download (704.31 kB)
journal contribution
posted on 11.04.2019, 08:01 by K Hirota, DG Lambert
Since Domino and colleagues reported the first clinical use of ketamine more than half a century ago there have been many clinical and laboratory studies to determine both mechanism(s) of action and the most appropriate clinically useful properties of this enigmatic drug. These include analgesia, favourable cardio-respiratory profile, anti-inflammatory effects and anti-cancer actions. In addition to this, anti-depressant actions of ketamine have been recognized that are of clinical applicability. In psychiatry, many clinical studies demonstrate that existing antidepressant medications show limited effectiveness and slow onset of clinical response. Indeed, development of new therapeutic strategies for major depression represents a major clinical need and represents an area where there is much pharmaceutical interest. Does ketamine fit the bill? In this editorial, this new facet is explored in terms of utility and mechanisms of actions.

History

Citation

Br J Anaesth, 2018, 121 (6), pp. 1198-1202

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Cardiovascular Sciences

Version

AM (Accepted Manuscript)

Published in

Br J Anaesth

Publisher

Elsevier

eissn

1471-6771

Acceptance date

28/08/2018

Copyright date

2018

Available date

12/10/2019

Publisher version

https://www.sciencedirect.com/science/article/pii/S0007091218306925?via=ihub

Notes

The file associated with this record is under embargo until 12 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.

Language

en